SCHEMBL12436239

SCHEMBL12436239

CN(C)C(=O)N(C)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATF1 P18846 1/20 0.42
NFKB1 P19838 1/20 0.42
TPMT P51580 1/20 0.38
ALDH1A1 P00352 3/20 0.37
FSCN1 Q16658 1/20 0.36
HTR3E A5X5Y0 1/20 0.35
HTR3B O95264 1/20 0.35
HTR3A P46098 1/20 0.35
HTR3D Q70Z44 1/20 0.35
HTR3C Q8WXA8 1/20 0.35
TSHR P16473 2/20 0.35
NOTUM Q6P988 1/20 0.34
TP53 P04637 1/20 0.34
TACR2 P21452 1/20 0.34
TACR1 P25103 1/20 0.34
TACR3 P29371 1/20 0.34
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
RXRG P48443 1/20 0.33
P2RX1 P51575 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12587458 0.88 ATF1 (0.35) ATF1NFKB1ALDH1A1FSCN1HTR3E
SCHEMBL12436222 0.82 P2RX1 (0.51) ATF1NFKB1ALDH1A1TP53TACR2
SCHEMBL2092289 0.80 ATF1 (0.43) ATF1NFKB1TPMTALDH1A1FSCN1
SCHEMBL2092292 0.80 TPMT (0.44) ATF1NFKB1TPMTALDH1A1FSCN1
SCHEMBL12435790 0.78 ALDH1A1 (0.47) ALDH1A1FSCN1TSHR
SCHEMBL11394132 0.75 ATF1 (0.40) ATF1NFKB1TPMTALDH1A1FSCN1
SCHEMBL2091610 0.75 ATF1 (0.40) ATF1NFKB1TPMTALDH1A1TSHR
SCHEMBL12436210 0.74 ALDH1A1 (0.35) ALDH1A1
SCHEMBL8091350 0.74 APEX1 (0.47) ALDH1A1FSCN1TSHRRXRARXRB
SCHEMBL22289622 0.74 GABRP (0.46) ATF1NFKB1TPMTALDH1A1HTR3E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-RE48334-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-12-01 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
EP-2336105-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME Takeda Pharmaceutical Company Limited (JP) 2011-06-22 EP disclosed
WO-2010032856-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME 武田薬品工業株式会社 (JP) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME NTSR2, BDKRB1, AVPR1B ATF1 3660/4885NFKB1 1164/4885TPMT 2212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.